In the dynamic landscape of the biotechnology sector, Abionyx Pharma SA stands out as a pioneering entity dedicated to the discovery and development of innovative therapies targeting renal and ophthalmological diseases. Headquartered in Balma, France, this company has carved a niche for itself since its inception in 2005, initially known as Cerenis Therapeutics Holding SA before adopting its current name in August 2019.
Abionyx Pharma SA’s strategic focus is on the development of several promising drug candidates, each designed to address critical unmet medical needs. Among these, CER-001 is particularly noteworthy. This therapeutic candidate is a negatively-charged lipoprotein particle that incorporates human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, along with sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids. The design of CER-001 aims to mimic the structural and functional biological properties of pre-beta HDL, positioning it as a potential treatment for post-acute coronary syndrome patients and those suffering from familial primary hypoalphalipoproteinemia.
In addition to CER-001, Abionyx Pharma SA is advancing CER-002, a peroxisome proliferator-activated receptor delta specific agonist. This candidate is being developed for the treatment of cardiovascular and metabolic diseases, reflecting the company’s commitment to addressing complex health challenges through targeted molecular interventions.
Another significant focus of the company is CER-209, a drug candidate aimed at treating metabolic diseases in the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis (NASH). The development of CER-209 underscores Abionyx Pharma SA’s dedication to expanding its therapeutic portfolio to encompass a broader range of metabolic disorders.
Financially, Abionyx Pharma SA is listed on the NYSE Euronext Paris, with its shares traded in euros. As of April 6, 2026, the company’s close price stood at 3.47 EUR, reflecting a market capitalization of approximately 122,362,320 EUR. Despite a challenging financial landscape, evidenced by a price-to-earnings ratio of -23.27, the company’s strategic initiatives and innovative pipeline continue to attract attention within the biotechnology sector.
The company’s journey from its founding in 2005 to its current status as a key player in the biotechnology industry highlights its resilience and adaptability. With a robust pipeline and a clear focus on addressing significant health challenges, Abionyx Pharma SA is poised to make substantial contributions to the field of healthcare, particularly in the realms of renal and ophthalmological therapies. As it continues to navigate the complexities of drug development, the company remains committed to its mission of improving patient outcomes through cutting-edge scientific research and innovation.
